What the research found
Researchers developed SASP Score, a machine learning–derived blood biomarker that quantifies the combined burden of senescence-associated secretory phenotype (SASP)—the inflammatory proteins released by senescent cells. Rather than measuring individual proteins, the algorithm accounts for how these markers interact in nonlinear ways, which is difficult to capture with conventional statistical approaches.
The team trained the model on data from nearly 51,000 participants in the UK Biobank, selecting 38 SASP-related proteins known to correlate with cellular senescence. They validated it on a separate cohort and found that higher SASP Scores predicted greater mortality risk (roughly 1.4× increased risk across all causes) and correlated with functional decline markers like grip strength, walking speed, and lung function. It also associated with specific age-related diseases, particularly chronic kidney disease, dementia, and stroke.
In a smaller intervention study of older adults, those who exercised regularly over 18 months showed flat SASP Scores, while sedentary controls showed significant increases, suggesting exercise may suppress circulating senescent cell burden.
Why it matters for you
If you're tracking biomarkers and optimizing lifespan, SASP Score offers a single-number read on systemic senescent cell load—something currently impossible to assess without a blood draw and lab analysis. Because it correlates with frailty, cardiovascular fitness, and mortality independent of age, it could become a useful complement to other aging clocks you monitor (like PhenoAge or proteomic measures).
The exercise finding is particularly relevant: it's one of the few interventions shown to actually slow SASP accumulation over time. If SASP Score becomes available through your biomarker tracking, consistent training stimulus would be one concrete way to monitor whether your protocol is working at the cellular level.
That said, SASP Score is general and systemic—a high score tells you senescent cell burden is elevated, but not where the problem is or which disease it predicts for you specifically. Use it as a trend metric alongside your other biomarkers, not as a diagnostic tool.
Caveats
- Early stage: This is a newly developed biomarker validated in observational cohorts; no randomized trials show that lowering SASP Score improves outcomes.
- Association, not causation: Higher SASP Score correlates with disease and mortality, but doesn't prove senescent cells are the cause.
- Limited intervention data: The exercise study was small and observational; effect sizes aren't provided.
- Not yet clinically available: SASP Score is a research tool; availability through commercial labs is unknown.
- Heterogeneous prediction: While it predicts mortality overall, it cannot specify which disease will manifest in an individual.